Portal de Periódicos da CAPES

Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

2018; Oxford University Press; Volume: 67; Issue: 10 Linguagem: Inglês

10.1093/cid/ciy585

1537-6591

Raymond T. Chung, Marc G. Ghany, Arthur Y. Kim, Kristen Marks, Susanna Naggie, Hugo E. Vargas, Andrew Aronsohn, Debika Bhattacharya, Tina Broder, Oluwaseun Falade‐Nwulia, Robert J. Fontana, Stuart C. Gordon, Theo Heller, Scott D. Holmberg, Ravi Jhaveri, Maureen M. Jonas, Jennifer J. Kiser, Benjamin P. Linas, Vincent Lo Re, Timothy R. Morgan, Ronald Nahass, Marion G. Peters, K. Rajender Reddy, Andrew Reynolds, John D. Scott, Gloria Searson, Tracy Swan, Norah A. Terrault, Stacey Trooskin, John B. Wong, Kimberly Workowski,

Liver Disease Diagnosis and Treatment

Recognizing the importance of timely guidance regarding the rapidly evolving field of hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) developed a web-based process for the expeditious formulation and dissemination of evidence-based recommendations. Launched in 2014, the hepatitis C virus (HCV) guidance website undergoes periodic updates as necessitated by availability of new therapeutic agents and/or research data. A major update was released electronically in September 2017, prompted primarily by approval of new direct-acting antiviral agents and expansion of the guidance's scope. This update summarizes the latest release of the HCV guidance and focuses on new or amended recommendations since the previous September 2015 print publication. The recommendations herein were developed by volunteer hepatology and infectious disease experts representing AASLD and IDSA and have been peer reviewed and approved by each society's governing board.